Jefferies Financial Group Inc. Purchases 29,696 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Jefferies Financial Group Inc. raised its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 65.5% in the 3rd quarter, Holdings Channel reports. The firm owned 75,000 shares of the company’s stock after buying an additional 29,696 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $2,970,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Keybank National Association OH boosted its position in shares of Teva Pharmaceutical Industries by 3.6% during the 3rd quarter. Keybank National Association OH now owns 21,276 shares of the company’s stock valued at $843,000 after acquiring an additional 744 shares during the last quarter. AlphaCore Capital LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter worth about $1,164,000. Fulcrum Asset Management LLP bought a new position in shares of Teva Pharmaceutical Industries in the third quarter worth approximately $803,000. M Holdings Securities Inc. bought a new position in shares of Teva Pharmaceutical Industries in the third quarter worth approximately $637,000. Finally, Brighton Jones LLC purchased a new stake in Teva Pharmaceutical Industries in the third quarter valued at approximately $227,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $43.52 on Friday. The firm has a market capitalization of $50.72 billion, a PE ratio of 101.22, a price-to-earnings-growth ratio of 4.05 and a beta of 0.97. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. Teva Pharmaceutical Industries Ltd. has a 12 month low of $24.01 and a 12 month high of $44.31. The business’s 50-day moving average price is $40.00 and its 200-day moving average price is $35.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The company had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. Teva Pharmaceutical Industries’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS. Sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TEVA shares. Zacks Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the company an “overweight” rating in a research report on Thursday. HC Wainwright initiated coverage on shares of Teva Pharmaceutical Industries in a report on Monday, November 2nd. They set a “buy” rating and a $52.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Finally, Leerink Partners upped their target price on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.15.

Teva Pharmaceutical Industries News Roundup

These are some of the TEVA news items that stood out recently:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and reiterated an Overweight rating, signaling confidence in further upside. Piper Sandler analyst ratings
• Neutral Sentiment: Healthcare stocks broadly declined Wednesday afternoon, a sector headwind that may have affected trading but does not reflect Teva-specific fundamentals. Healthcare sector update
• Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.6 million, reducing his stake by 21.23%. EVP Richard Daniell also sold 20,003 shares and 25,000 shares in separate transactions. These sizable insider sales may raise concerns about executive confidence, although the filings do not state the reasons for the transactions. CEO SEC filing EVP SEC filing

Insider Activity

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mark Sabag sold 46,000 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the completion of the sale, the insider owned 80,760 shares of the company’s stock, valued at approximately $3,386,266.80. The trade was a 36.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 715,945 shares of company stock valued at $29,061,351. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.